CLOPID

Clopidogrel selectively inhibits the binding of ADP (Adenosine Diphosphate) to its platelet receptor and the subsequent ADP mediated activation of glycoprotein GP IIb / IIIa complex, thereby inhibiting platelet aggregation. Clopidogrel has received a USFDA approval in patients with acute STEMI (ST Segment Elevated Myocardial Infarction)